Background: Transcatheter aortic valve replacement (TAVR) is well-established for aortic stenosis, while its application for isolated native aortic regurgitation (AR) was previously off-label and technically challenging. Comparative data between TAVR and surgical AVR (SAVR) are limited.
Objectives: To compare patient characteristics and outcomes of off-label TAVR vs. SAVR among patients with isolated native AR.
Methods: Using the Centers for Medicare & Medicaid Services (CMS) Medicare Provider Analysis and Review (MedPAR) database, we identified patients ≥ 65 years who underwent TAVR or SAVR for isolated native AR (2017-2023). Propensity score matching (1:1) was performed to evaluate short- and long-term outcomes. Fine-Gray models accounted for death as a competing risk, reported as subdistribution hazard ratios (SHRs).
Results: Among 9,859 patients, 1,742 propensity-score matched pairs were included, with balanced baseline characteristics (mean age 75.8 vs. 75.7 years; female sex, 517/1,742 [29.7%] vs. 528/1,742 [30.3%]). In the matched cohort, TAVR was associated with shorter hospitalization (OR 0.33; 95% CI, 0.28-0.39; p<0.001) and lower in-hospital mortality (OR 0.62; 95% CI, 0.39-1.00; p=0.048) but higher 30-day pacemaker implantation (OR 1.73; 95% CI, 1.33-2.25; p<0.001). Through 5 years (median follow-up, 2.58 years), TAVR was associated with increased repeat AVR (SHR 2.04; 95% CI, 1.13-3.66) but similar all-cause mortality (HR 1.14; 95% CI, 0.98-1.31) or heart failure-related readmission (SHR 1.09; 95% CI, 0.98-1.21) between treatment strategies.
Conclusions: In this analysis, TAVR was associated with shorter hospitalization and comparable 5-year survival to SAVR, although higher pacemaker and long-term reinterventions rates.
Editors
Editor-in-Chief
Harlan M. Krumholz, MD, SM, FACC
CME Editor
Ragavendra R. Baliga, MD
Author
Harun Kundi, MD, MMSc
Important Dates
Date of Release: November 9, 2026
Term of Approval/Date of CME/MOC Expiration: November 8, 2027